FindTrial
Sign In

A clinical trial to study the effects Flecainide on HV interval in patients with symptomatic Bifascicular block

Role of Flecainide in assessment of atrioventricular conduction in symptomatic bifascicular block

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/12/029543
Enrollment
50
Registered
2020-12-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I452- Bifascicular block

Interventions

Intervention1: Flecainide: Tab flecainide 300 mg Route - oral Then HV interval will be seen at 30 min , 1 hr , 2 hrs , 3 hrs

Sponsors

King George Medical University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: study population will consist of symptomatic patient admitted with bifasicular block for permanent pacing

Exclusion criteria

Exclusion criteria: patient with established indication for pacing. 1- Third degree AV block( CHB) 2- Mobitz II 3-Advanced AVB 4-LVEF <35%

Design outcomes

Primary

MeasureTime frame
to access the effect of flecainide on infrahasian AV conductionTimepoint: during the study- Via measurement of HV interval 100 or more than 100 after flecainide .—

Secondary

MeasureTime frame
to know the effect of incremental pacing on HV interval in patients with BFB after flecainideTimepoint: at the end of study—

Countries

India

Contacts

Public ContactDrDeepak

Dept Of Cardiology King Georges Medical University

dr_skdwivedi@rediffmail.com9935037620

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026